A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT02957474
- Locations
- 🇬🇧
Richmond Pharmacology, Ltd., Croydon, Surrey, United Kingdom
A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain
- Conditions
- Multiple Myeloma
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 355
- Registration Number
- NCT02946333
- Locations
- 🇪🇸
Hospital Puerto Real, Puerto Real, Andalusia, Spain
🇪🇸Hospital ICO Durán y Reynals, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital de la Princesa, Madrid, Comunidad De Madrid, Spain
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1
- Registration Number
- NCT02935790
- Locations
- 🇺🇸
NYU Langone Medical Center, New York, New York, United States
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT02934269
- Locations
- 🇺🇸
PPD Phase 1 Unit, Austin, Texas, United States
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
- Conditions
- Multiple Myeloma
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 361
- Registration Number
- NCT02922543
- Locations
- 🇯🇵
Shinko Hospital, Kobe, Hyogo, Japan
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
- Conditions
- Multiple Myeloma
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1149
- Registration Number
- NCT02921828
- Locations
- 🇯🇵
Shinko Hospital, Kobe, Hyogo, Japan
🇺🇸Local Institution - Japan, No City Provided, New Jersey, United States
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
- Conditions
- Multiple MyelomaMyelodysplastic Syndromes
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 4626
- Registration Number
- NCT02921802
- Locations
- 🇯🇵
Shinko Hospital, Kobe, Hyogo, Japan
A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 84
- Registration Number
- NCT02921815
- Locations
- 🇯🇵
Shinko Hospital, Kobe, Hyogo, Japan
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
- Conditions
- GlioblastomaMalignant Glioma
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 66
- Registration Number
- NCT02903069
- Locations
- 🇺🇸
Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States
🇺🇸Northwestern Center For Clinical Research, Chicago, Illinois, United States
🇺🇸John Wayne Cancer Center Outpatient Clinic, Santa Monica, California, United States
An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice
- Conditions
- Multiple Myeloma
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 2504
- Registration Number
- NCT02902900
- Locations
- 🇫🇷
Centre Hospitalier General, Saint Germain En Laye, France
🇫🇷Centre Hospitalier H. Duffaut, Avignon Cedex 9, France
🇫🇷Centre Hospitalier Intercommunal Robert Ballanger, Aulnay Sous Bois, France